The direct action of ondansetron on the inhibition of PTP1B activity contributes to laying down the foundation that this metabolic pathway can be instrumental in treating conditions like NAFLD and diabetes, as proposed in our earlier studies (Agouni et al., 2011; 2014; Abdelsalam et al., 2021). This evidence concerns the gene PTPN1 and metabolic dysfunction-associated steatotic liver disease.